FAIRFIELD, N.J., Oct. 6 /PRNewswire-FirstCall/ -- Bradley Pharmaceuticals, Inc. today announced that the Company’s Doak Dermatologics subsidiary has partnered with the Foundation for Ichthyosis & Related Skin Types (FIRST) for the second year in a row. This cooperative effort was designed to raise awareness of serious dry skin conditions and was inaugurated during National Ichthyosis Week in 2003. The presence of Doak Dermatologics during the current National Ichthyosis Week serves to reinforce the solid partnership between the Foundation and the Company.
Bradley Pharmaceuticals supports FIRST in their mission of supplying educational information on ichthyosis to physicians and patients. Bradley’s Doak Dermatologics subsidiary has provided the Foundation with literature and coordinating extensive physician consciousness-raising campaigns throughout the past year. Doak also mobilized its field force of professional representatives to visit dermatologists’ offices, providing educational materials and patient information about the many Foundation-supported activities. This campaign has proved to be highly successful and will be strengthened substantially throughout the upcoming year.
Ichthyosis is a genetic skin disease characterized by dry, thickened, scaly skin. The condition affects over 1 million Americans and can be severely disfiguring, causing numerous social and psychological implications.
Doak Dermatologics’ Vice President and General Manager, John Garrigan, stated, “Doak Dermatologics has been most supportive in furthering efforts to reinforce the message of ichthyosis research, family support and treatment to both doctors and patients. We look forward to a long association with FIRST (http://www.scalyskin.org/) that will benefit their members and improve the awareness and treatment of ichthyosis.”
Ichthyosis is an area of special concern for Doak as the providers of Keralac(TM), a 35% Urea-based lotion in a unique vehicle containing Vitamin E, Lactic Acid and Zinc. Keralac(TM) Lotion promotes a favorable pH level to provide a beneficial healing environment for dry skin. Since its introduction in 2004, Keralac(TM) Lotion has been the choice of many dermatologists in the treatment of mild to moderate cases of ichthyosis.
Bradley Pharmaceuticals, Inc. , was founded in 1985 as a specialty pharmaceutical company marketing to niche physician specialties in the U.S. and 38 international markets. Bradley’s success is based on the strategy of Acquire, Enhance and Grow. Bradley Acquires non-strategic brands, Enhances these brands with line extensions and improved formulations and Grows the products through promotion, advertising and selling activities to optimize life cycle management. Bradley Pharmaceuticals has two operating units: Doak Dermatologics, specializing in topical therapies for dermatology and podiatry, and Kenwood Therapeutics, providing gastroenterology, respiratory and other internal medicine brands.
Important announcement:
To view the Business World Review interview with Daniel Glassman, visit: http://www.bradpharm.com/
Please visit Bradley Pharmaceuticals web site at: http://www.bradpharm.com/
Bradley Pharmaceuticals common stock is listed on the NYSE under the symbol BDY.
Except for historical and factual information, this press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements that address activities, events or developments that Bradley expects, believes or anticipates will or may occur in the future, such as earnings estimates, launches of new products, market acceptance of products, and predictions of future financial performance. All forward-looking statements are based on assumptions made by Bradley based on its experience and perception of historical trends, current conditions, expected future developments and other factors it believes are appropriate under the circumstances. These statements are subject to numerous risks and uncertainties, many of which are beyond Bradley’s control, including Bradley’s ability to maintain sales and the introduction of new and future competing products, whether branded, or generic, or comparable, effectively purchase or integrate new products into its portfolio or effectively react to other risks described from time to time in Bradley’s SEC filings. Further, Bradley cannot predict the impact on its business of any introduction, or future approvals, of generic or therapeutically equivalent or comparable versions of its products or of other competing products. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Bradley undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Bradley Pharmaceuticals, Inc.
CONTACT: Anthony Griffo, Investor Relations of Bradley Pharmaceuticals,Inc., +1-973-882-1505, ext. 313